Latest Market Growth News

Eureka Group Holdings has acquired Emerald Tourist Park in Queensland, marking its sixth acquisition since a major capital raise and reinforcing its strategy in affordable rental accommodation.

Amaero has successfully qualified its C103 and Ti64 metal powders through a collaboration with Auburn University’s NCAME, meeting Velo3D’s standards and paving the way for initial commercial shipments in FY2026.

archTIS Limited has secured A$7.5 million through a discounted share placement to fund expansion in the U.S. defence sector, deepen strategic partnerships, and accelerate product innovation focused on secure data collaboration.

Southern Cross Media Group has finalized the sale of its remaining television assets, fully committing to its 'All About Audio' strategy with a 5% rise in audio revenues for FY25 and a renewed focus on debt reduction and dividends.

Xero has completed a significant A$1.85 billion institutional placement to fund its acquisition of Melio, aiming to enhance its accounting and payments platform in the US market. A complementary A$200 million Share Purchase Plan will offer retail investors a chance to participate.

Bioxyne Limited's subsidiary Breathe Life Sciences has achieved key GMP certifications across multiple international markets, paving the way for expanded operations in Europe, the UK, Canada, and Singapore. The company signals strong growth prospects for FY2026, with formal guidance expected in August.

4DMedical has renewed and expanded its contract with Stanford University’s 3DQ Lab to include its innovative CT – VQ™ imaging technology ahead of FDA clearance, marking a significant step in its U.S. market expansion.

Minbos Resources reports strong 2024-25 field trial results for its phosphate fertilizer PRIMEIRO™ in Angola, while expanding its product range with PRIMEIRO PLUS+, a blended NPKS solution tailored to local soils and crops.

Accent Group reports a modest decline in like-for-like sales and margin compression in the second half of FY25, setting full-year EBIT guidance between $108 million and $111 million.

Challenger Limited has welcomed APRA’s consultation on new capital settings for annuity products, highlighting the potential for regulatory reforms to boost innovation and growth in Australia’s retirement income sector.

ASX Limited’s 2025 Investor Forum reveals steady progress on its five-year strategy, highlighting technology modernization, operational risk management, and a focus on data-driven growth. The exchange outlines capital expenditure plans and expense controls aimed at sustaining shareholder value amid evolving market demands.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.